Can AI generate personalized cancer treatment regimens from genomic and clinical trial data ?

Can artificial intelligence reliably generate individualized cancer treatment plans by cross-referencing a patient’s genomic profile with data from published clinical trials? This question probes the balance between promising computational outputs and the rigorous medical standards required for patient care.

Background

Artificial intelligence models are increasingly used to integrate patient-specific DNA sequencing and tumor mutation profiles with evidence from peer-reviewed clinical trials to suggest personalized drug combinations. These systems utilize machine learning algorithms to identify potentially effective therapies by matching genomic alterations to drugs with reported efficacy in similar patient cohorts. For instance, deep learning frameworks such as DeepDR and similar platforms have been developed to predict drug responses based on multi-omics data and historical trial outcomes. However, concerns persist about the clinical validity and real-world efficacy of AI-generated regimens, as highlighted by oncologists and regulatory bodies. While these models can produce plausible drug pairings by learning from large datasets, critics argue that many suggestions lack prospective validation in controlled clinical settings or demonstrated survival benefits in patients. Additionally, the heterogeneity of cancer types, the dynamic nature of tumor evolution, and the variability in trial designs further complicate the translation of AI recommendations into standardized treatment protocols. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) have emphasized the need for rigorous validation of AI-driven clinical decision support tools to ensure patient safety and therapeutic benefit.

Large language models and other AI systems are increasingly used to synthesize biomedical literature and clinical-trial reports to propose treatment options. Benchmarking studies report that AI can retrieve and rank relevant trial arms for a given patient genotype with moderate-to-high accuracy, though performance varies by cancer type and data completeness. Regulatory pathways for software that generates treatment recommendations remain fragmented, with some jurisdictions treating such systems as clinical decision support tools and others as high-risk medical devices. Real-world validation typically involves retrospective chart reviews and prospective pilot studies comparing AI-suggested regimens to those chosen by multidisciplinary tumor boards. Ethical and legal guidance emphasizes the need for explainability, human oversight, and clear disclosure when AI is used to inform care. Data sources include public repositories such as TCGA and cBioPortal, as well as structured trial databases like ClinicalTrials.gov and EudraCT.

— Enriched May 15, 2026 · Source: Nature Biotechnology, 2023